These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 23717610)

  • 1. BcL-xL conformational changes upon fragment binding revealed by NMR.
    Aguirre C; Ten Brink T; Walker O; Guillière F; Davesne D; Krimm I
    PLoS One; 2013; 8(5):e64400. PubMed ID: 23717610
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NMR structural investigation of the mitochondrial outer membrane protein VDAC and its interaction with antiapoptotic Bcl-xL.
    Malia TJ; Wagner G
    Biochemistry; 2007 Jan; 46(2):514-25. PubMed ID: 17209561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chelerythrine and sanguinarine dock at distinct sites on BclXL that are not the classic BH3 binding cleft.
    Zhang YH; Bhunia A; Wan KF; Lee MC; Chan SL; Yu VC; Mok YK
    J Mol Biol; 2006 Dec; 364(3):536-49. PubMed ID: 17011577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Auto-FACE: an NMR based binding site mapping program for fast chemical exchange protein-ligand systems.
    Krishnamoorthy J; Yu VC; Mok YK
    PLoS One; 2010 Feb; 5(2):e8943. PubMed ID: 20174626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A combination of in silico and SAR studies to identify binding hot spots of Bcl-xL inhibitors.
    Levoin N; Vo DD; Gautier F; Barillé-Nion S; Juin P; Tasseau O; Grée R
    Bioorg Med Chem; 2015 Apr; 23(8):1747-57. PubMed ID: 25797160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural basis for the interaction between DJ-1 and Bcl-X
    Lee MK; Lee MS; Bae DW; Lee DH; Cha SS; Chi SW
    Biochem Biophys Res Commun; 2018 Jan; 495(1):1067-1073. PubMed ID: 29175327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heat-induced dimerization of BCL-xL through alpha-helix swapping.
    Denisov AY; Sprules T; Fraser J; Kozlov G; Gehring K
    Biochemistry; 2007 Jan; 46(3):734-40. PubMed ID: 17223694
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bh3 induced conformational changes in Bcl-Xl revealed by crystal structure and comparative analysis.
    Rajan S; Choi M; Baek K; Yoon HS
    Proteins; 2015 Jul; 83(7):1262-72. PubMed ID: 25907960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting of p53 peptide analogues to anti-apoptotic Bcl-2 family proteins as revealed by NMR spectroscopy.
    Shin JS; Ha JH; Chi SW
    Biochem Biophys Res Commun; 2014 Jan; 443(3):882-7. PubMed ID: 24342622
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cryptic-site binding mechanism of medium-sized Bcl-xL inhibiting compounds elucidated by McMD-based dynamic docking simulations.
    Bekker GJ; Fukuda I; Higo J; Fukunishi Y; Kamiya N
    Sci Rep; 2021 Mar; 11(1):5046. PubMed ID: 33658550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In silico SELEX screening and statistical analysis of newly designed 5mer peptide-aptamers as Bcl-xl inhibitors using the Taguchi method.
    Poustforoosh A; Faramarz S; Nematollahi MH; Hashemipour H; Negahdaripour M; Pardakhty A
    Comput Biol Med; 2022 Jul; 146():105632. PubMed ID: 35617726
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural insights into mouse anti-apoptotic Bcl-xl reveal affinity for Beclin 1 and gossypol.
    Priyadarshi A; Roy A; Kim KS; Kim EE; Hwang KY
    Biochem Biophys Res Commun; 2010 Apr; 394(3):515-21. PubMed ID: 20206602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel mechanism of irinotecan targeting MDM2 and Bcl-xL.
    Lee B; Min JA; Nashed A; Lee SO; Yoo JC; Chi SW; Yi GS
    Biochem Biophys Res Commun; 2019 Jun; 514(2):518-523. PubMed ID: 31056264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Computational analysis of binding free energies, hotspots and the binding mechanism of Bcl-xL/Bcl-2 binding to Bad/Bax.
    Duan L; Dong S; Huang K; Cong Y; Luo S; Zhang JZH
    Phys Chem Chem Phys; 2021 Jan; 23(3):2025-2037. PubMed ID: 33469639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiple ligand simultaneous docking: orchestrated dancing of ligands in binding sites of protein.
    Li H; Li C
    J Comput Chem; 2010 Jul; 31(10):2014-22. PubMed ID: 20166125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NMR characterization of the interaction between Bcl-x
    Kusunoki H; Tanaka T; Kohno T; Kimura H; Hosoda K; Wakamatsu K; Hamaguchi I
    Biochem Biophys Res Commun; 2019 Oct; 518(3):445-450. PubMed ID: 31439373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploring the conformational and binding properties of unphosphorylated/phosphorylated monomeric and trimeric Bcl-2 through docking and molecular dynamics simulations.
    Zacarías-Lara OJ; Correa-Basurto J; Bello M
    Biopolymers; 2016 Jul; 105(7):393-413. PubMed ID: 27016043
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of novel potent inhibitors against Bcl-xL anti-apoptotic protein using docking studies.
    Shipra G; Gauri M; Chandra PM; Kishore SP
    Protein Pept Lett; 2012 Dec; 19(12):1302-17. PubMed ID: 22670675
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The N-terminal domain of tumor suppressor p53 is involved in the molecular interaction with the anti-apoptotic protein Bcl-Xl.
    Xu H; Tai J; Ye H; Kang CB; Yoon HS
    Biochem Biophys Res Commun; 2006 Mar; 341(4):938-44. PubMed ID: 16455050
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rational design and structure-activity relationship studies of quercetin-amino acid hybrids targeting the anti-apoptotic protein Bcl-xL.
    Kellici TF; Chatziathanasiadou MV; Lee MS; Sayyad N; Geromichalou EG; Vrettos EI; Tsiailanis AD; Chi SW; Geromichalos GD; Mavromoustakos T; Tzakos AG
    Org Biomol Chem; 2017 Sep; 15(37):7956-7976. PubMed ID: 28902204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.